Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.14811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Nobuaki Mamesaya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Carboplatin plus etoposide is a standard treatment for older extensive‐stage small‐cell lung cancer (ES‐SCLC) patients with performance status (PS) 2. However, older patients often exhibit poor PS (3, 4), and the treatment effect in them is poorly understood. To determine the therapeutic efficacy and safety of carboplatin plus etoposide therapy for this population, we retrospectively analyzed 63 patients with ES‐SCLC with PS ≥2, aged ≥71 years, who had received first‐line carboplatin plus etoposide therapy. We compared the treatment efficacy and safety in patients with baseline PS 2 versus those with PS 3–4. In the PS 2 (38 patients) and PS ≥3 (25 patients) groups, the overall response rate was 71.1% and 72.0%, median progression‐free survival was 4.6 and 3.1 months, and overall survival was 7.7 and 5.1 months, respectively. PS improved to 0–1 post‐treatment in 65.8% and 48.0% of the patients in the PS 2 and PS ≥3 groups, respectively. Patients with PS ≥3 showing improved PS had a progression‐free survival of 6.1 months. A higher incidence of grade ≥3 decreased neutrophil counts, febrile neutropenia, and treatment‐related death was observed in the PS ≥3 group. The progression‐free survival of patients administered prophylactic granulocyte colony‐stimulating factor (G‐CSF) was 5.2 and 6.1 months in the PS2 and PS ≥3 groups. Overall, carboplatin plus etoposide therapy provided comparable tumor shrinkage, but shorter progression‐free and overall survival in older ES‐SCLC patients with PS ≥3 than in those with PS 2. Thus, supportive care, such as prophylactic G‐CSF administration, may be necessary to ensure safety and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, Japan.
ORCID-Profile: Tateaki Naito, Tetsuo Shimizu, Toshiaki Takahashi
Zitieren
APA
Mamesaya, N., Kodama, H., Iida, Y., Kobayashi, H., Ko, R., Wakuda, K., Ono, A., Kenmotsu, H., Naito, T., Murakami, H., Shimizu, T., Gon, Y., & Takahashi, T. (2023). Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14811
Vancouver
Mamesaya N, Kodama H, Iida Y, Kobayashi H, Ko R, Wakuda K, et al. Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14811
BibTeX
@article{Mamesaya2023,
author = {Mamesaya, Nobuaki and Kodama, Hiroaki and Iida, Yuko and Kobayashi, Haruki and Ko, Ryo and Wakuda, Kazushige and Ono, Akira and Kenmotsu, Hirotsugu and Naito, Tateaki and Murakami, Haruyasu and Shimizu, Tetsuo and Gon, Yasuhiro and Takahashi, Toshiaki},
title = {Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.14811}
}
EUVIMED